Overlake Medical Center & Clinics and Seattle Cancer Care Alliance (SCCA) recently launched a joint cancer treatment program to bring cutting-edge cancer care to the Bellevue hospital, a collaboration first announced in January.
“A central part of our mission is to ensure people have access to the best cancer treatments as close to their community and loved ones as possible,” Dr. Nancy Davidson, executive director and president of SCCA, said in a news release. “We are excited to combine SCCA’s world-class cancer program with the outstanding cancer care environment at Overlake to provide patients on the Eastside with the most advanced cancer care treatments provided by the best specialists.”
SCCA will provide hematology/medical oncology and infusion services, while Overlake will continue to provide radiation oncology, surgical oncology, inpatient oncology care and ancillary services, such as imaging and physical therapy, the release said.
“Overlake is committed to innovating and collaborating with community partners in ways that advance the care we provide to the Eastside,” Overlake President and CEO J. Michael Marsh said in the release. “This affiliation is founded on the shared values and care philosophies of the two organizations.”
As Washington’s only National Cancer Institute-designated cancer center, SCCA brings together the leading research teams and cancer specialists from Fred Hutchinson Cancer Research Center, Seattle Children’s and UW Medicine, according to the release.
Through the alliance, Overlake patients will have greater availability of clinical trials, where they might access some groundbreaking advances in medical science and potentially access new drugs for cancer treatment, Dr. Kristi Harrington, medical director of cancer services at Overlake, said in video comments provided by Overlake.
“Now, of course, that’s not going to happen in every single patient, not every patient needs a clinical trial, nor is there a clinical trial that’s appropriate for every patient,” she said. “And, we can’t forget that not all patients want to be on a clinical trial.”
Added Harrington, “Our goal at the Overlake cancer center is to of course always follow evidence-based treatment guidelines to look at clinical pathways, to collaborate in the care of the patient and I think what this partnership really shows is SCCA trusts us, right? I mean they want to be our partner.”
SCCA will provide services at the Overlake Cancer Center in Bellevue, a state- of-the-art facility that received a $20 million upgrade in 2017.
Overlake’s overall campus is undergoing a $250 million, five-year renewal project slated for completion in 2022. The three-phase construction project, known as Project FutureCare, began in 2017, includes a new hospital tower that was topped off in December.